about us
More Reyra Co. Limited, established in 2000, is a research-driven biopharmaceutical company that produces Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. From its beginnings as a single-product company, More Reyra has evolved into a comprehensive solution provider, offering a diverse range of products across various therapeutic segments.
Globally recognized for its high-quality products, More Reyra operates in over 70 countries. The company has an efficient distribution network covering markets such as the USA, Europe, Japan, Latin America, Africa, and Asia, along with a strong presence in India. More Reyra continues to expand its reach by partnering with leading global pharmaceutical companies, addressing their product development needs for APIs and finished formulations.
For APIs, our R&D efforts concentrate on:
- Fermentation technology, encompassing strain enhancement, media optimization, process development, scaling up processes, technology transfer at commercial scale, and process enhancement.
- Chemical processes, covering downstream process development, semi-synthetic process development, non-infringing process development, yield improvement, analytical method development and validation, impurity profiling, method transfer to quality control, and commercial-scale technology transfer.
Regarding formulations, our R&D activities focus on:
- Formulation development, encompassing immediate and extended-release oral solids, oral liquids, topical ointments, creams, and liquid, lyophilized, and dry powder injectables.
- Analytical capabilities, including physical, chemical, microbiological, and instrumental analyses as per current Good Laboratory Practices (cGLP) requirements, development and validation of stability indicating methods, and studies on material compatibility.
Utilizing our robust R&D capabilities, we provide comprehensive contract research and manufacturing services that encompass:
- Enhancing strains for improved performance;
- Optimizing media for enhanced efficiency;
- Developing and optimizing processes to achieve cost-effectiveness and efficiency;
- Scaling up processes to commercial production levels;
- Developing optimized biotransformation processes; and
- Conducting pre-formulation and formulation development for a broad spectrum of sterile and non-sterile dosage forms tailored for global markets.
